Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2008

WuXi PharmaTech to Acquire AppTec Laboratory Services for $151M

  • WuXi PharmaTech plans to buy AppTec Laboratory Services in a deal valued at $151 million. The acquisition adds biologics capabilities to WuXi PharmaTech’s services. The firm will also gain a significant U.S. operational footprint.

    It is expected that the combined business operations of WuXi PharmaTech and AppTec in the U.S. and China will enable WuXi PharmaTech to provide a full-service suite of outsourced chemistry and biology services to global pharmaceutical, biotechnology, and medical device clients.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »